These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9718230)

  • 1. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
    Schmidt BH; Heinig R
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():15-9. PubMed ID: 9718230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metrifonate: a new agent for the treatment of Alzheimer's disease.
    Williams BR
    Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
    Pettigrew LC; Bieber F; Lettieri J; Wermeling DP; Schmitt FA; Tikhtman AJ; Ashford JW; Smith CD; Wekstein DR; Markesbery WR; Orazem J; Ruzicka BB; Mas J; Gulanski B
    J Clin Pharmacol; 1998 Mar; 38(3):236-45. PubMed ID: 9549662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.
    Heinig R; Sachse R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):456-64. PubMed ID: 10507245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
    McKeith IG
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacology of metrifonate.
    Jann MW
    Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.
    Cutler NR; Jhee SS; Cyrus P; Bieber F; TanPiengco P; Sramek JJ; Gulanski B
    Life Sci; 1998; 62(16):1433-41. PubMed ID: 9585171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating response to metrifonate.
    Tariot PN
    J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metrifonate for Alzheimer's disease patients.
    Schneider LS
    J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
    [No Abstract]   [Full Text] [Related]  

  • 10. Metrifonate: overview of safety and efficacy.
    Cummings JL
    Pharmacotherapy; 1998; 18(2 Pt 2):43-6; discussion 79-82. PubMed ID: 9543464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
    Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metrifonate: update on a new antidementia agent.
    Ringman JM; Cummings JL
    J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
    Gélinas I; Gauthier S; Cyrus PA
    J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
    Piecoro LT; Wermeling DP; Schmitt FA; Ashford JW
    Pharmacotherapy; 1998; 18(5):1129-32. PubMed ID: 9758325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
    Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
    Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
    Sandson TA
    Neurology; 1999 Feb; 52(3):675-6. PubMed ID: 10025821
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
    Cummings JL; Nadel A; Masterman D; Cyrus PA
    J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
    Knopman DS
    Neurology; 1998 May; 50(5):1203-5. PubMed ID: 9595961
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group.
    Blass JP; Cyrus PA; Bieber F; Gulanski B
    Alzheimer Dis Assoc Disord; 2000; 14(1):39-45. PubMed ID: 10718203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.